C. Zhao

发表

Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone.

X. F. Liu, T. Lu, C. Chen, 2009, The British journal of radiology.

Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.

W. Liang, Ying Huang, Jing Zhang, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity.

E. Perez, S. Chan, J. Hamm, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

G. Sonpavde, M. Ernstoff, M. Carducci, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial.

X. Chen, M. Chua, H. Mai, 2019 .

OP0022 Abatacept sc versus adalimumab on background methotrexate in RA: One year results from the ample study

D. M. van der Heijde, M. Weinblatt, M. Schiff, 2013 .

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

G. Mills, M. Ladanyi, C. Paweletz, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.

B. O'Sullivan, E. Tan, L. Siu, 2011, European journal of cancer.

The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study

Jun Ma, J. Ma, C. Qian, 2014, British Journal of Cancer.

LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy.

P. Atadja, R. Johnstone, D. George, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superficial parotid lobe-sparing delineation approach: a better method of dose optimization to protect the parotid gland in intensity-modulated radiotherapy for nasopharyngeal carcinoma.

W. Xia, Y. Xiang, C. Zhao, 2013, Current oncology.

1-2-3 - Untitled.123

Zhang, Chen, H. Liang, 2010 .

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

G. Mills, M. Ladanyi, C. Paweletz, 2019 .

1022PDEVELOPMENT AND VALIDATION OF A NOMOGRAM FOR PREDICTING OVERALL SURVIVAL OF PATIENTS WITH NON-METASTATIC NASOPHARYNGEAL CARCINOMA AFTER CURATIVE THERAPY.

W. Liang, C. Zhao, X. Wu, 2014, Annals of Oncology.

LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

P. Atadja, L. Ellis, R. Johnstone, 2006 .

The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).

G. Rustin, I. Vergote, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.